Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

PENBullishIndustry Newsnews

High materiality8/10

Penumbra THUNDERBOLT results show strong ELVO performance and regulatory tailwinds

Jul 22, 2026, 2:37 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Strong clinical data and regulatory progress could drive near-term upside on adoption and pricing assumptions, with potential multiple expansion if guidance improves.

AI summary

What happened, with direct paths to the underlying reporting

Penumbra reports THUNDERBOLT IDE results for its CAVT system in emergent large vessel occlusion stroke, with high reperfusion rates and fast revascularization. Key metrics include 87.5% reperfusion (mTICI 2b-3), median 20-minute time-to-revascularization, 83% clot ingestion, and low adverse-event rates. FDA clearance and CE Mark imply regulatory momentum and potential for accelerated adoption, supporting PEN's longer-term growth trajectory.

THUNDERBOLT IDE study on Penumbra's CAVT shows high reperfusion in ELVO.
87.5% mTICI 2b-3 reperfusion; 70.4% mTICI 2c-3 post-THUNDERBOLT.
Median time-to-revascularization: 20 minutes; first-pass mTICI 2b-3 64.8%.
Complete clot ingestion 83%; SAE 2.8%, sICH 0.9%, 90-day mortality 11.7%.
FDA clearance and CE Mark bolster THUNDERBOLT adoption; potential upside for PEN.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Penumbra THUNDERBOLT results show strong ELVO performance and regulatory tailwinds

Boston Scientific to Acquire Penumbra for $14.5 Billion in Medtech Deal

Penumbra Among Well-Insulated Companies From Ongoing Tariff Dynamics, Says Analyst

Penumbra Is Poised For Growth As Blood Clot Awareness Rises: Analyst